HIV mutation literature information.


  Transmitted Drug Resistance Mutations in Antiretroviral-Naive Injection Drug Users with Chronic HIV-1 Infection in Iran.
 PMID: 25962088       2015       PloS one
Table: K219E
Discussion: In contrast to these earlier reports that identified a limited number of NRTI mutations (T215D, K219Q and D67G, V75A) with a low overall frequency (4.2% and 5.1%, respectively) in newly infected Iranian cases, we detected a variety of NRTI SDRMs (M41L, D67N, K70R, V75M, F116Y, M184V, L210W, T215Y, and K219E) with a higher overall frequency (10%) in chronically infected IDUs in the city of Sanandaj (Table 2).


  HIV-1 subtype characteristics of infected persons living in southwestern Greece.
 PMID: 26715861       2015       HIV/AIDS (Auckland, N.Z.)
Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and


  Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
 PMID: 25754408       2015       Journal of medical virology
Result: A wide range of mutations conferring multi-NRTI resistance were also observed, including M41L (n = 7, 10%), A62V (n = 15, 22%), D67N (n = 10, 15%), K70R (n = 10, 15%), V75I (n = 2, 3%), F77L (n = 1, 1%), Y115F (n = 6, 9%), F116Y (n = 1, 1%), Q151M (n = 1, 1%), L210W (n = 3, 4%), T215Y/F (n = 7, 10%) and (n = 5, 7%), and K219Q/E (n = 4, 6%) and (n = 7, 10%).


  Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
 PMID: 26107265       2015       PloS one
Table: K219E


  HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
 PMID: 25141905       2014       Journal of the International AIDS Society
Introduction: There are two TAM pathways: type I (M41L, L210W and T215Y) and type II (D67N, K70R, T215F and K219Q/E); the former conferring higher levels of resistance and cross-resistance.
Result: A total of 35 patients had at least 1 TAM, with the following distribution: M41L (16%), D67N (15%), K70R (9%), L210W (11%), T215Y (16%), T215F (11%), K219Q (5%) and K219E (2%).


  The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance.
 PMID: 25341667       2014       Viruses
Introduction: Several mutations (the thymidine analog mutations, TAM) are required for high-level AZT resistance by excision, and include M41L, D67N, K70R, T215F or Y and K219E or Q.


  Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey.
 PMID: 25397495       2014       Journal of the International AIDS Society
Abstract: However, thymidine analogue resistance mutations (TAMs) determined two distinct genotypic profiles in the HIV-1 reverse transcriptase: TAM1: M41L, L210W and T215Y, and TAM2: D67N, K70R, K219E/Q, and T215F.


  Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.
 PMID: 25397500       2014       Journal of the International AIDS Society
Table: K219E


  Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
 PMID: 25575025       2014       Retrovirology
Table: K219E


  2014 Update of the drug resistance mutations in HIV-1.
 PMID: 25101529       2014       Topics in antiviral medicine
Discussion: Mutations known to be selected by TAMs (ie, M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E) also confer reduced susceptibility to all currently approved nRTIs.
Discussion: The presence of 3 of the following mutations:M41L, D67N, L210W, T215Y/F, K219Q/E:is associated with resistance to didanosine.



Browser Board

 Co-occurred Entities




   Filtrator